Research never stops

Top Story

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan)

Hamburg, Germany, 19 January 2017: Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

- read more

Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics

Toronto, Canada and Hamburg, Germany, 17 January 2017: Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.

- read more

HaplogenĀ“s novel antiviral target partnered with Evotec published in 'Nature'

Vienna/Amsterdam/Hamburg, 12 January 2017: Evotec AG  today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.

- read more
loading weather report
Loading weather report...


Jan 31, 2017 - High-Tech Partnering Conference 2017

Feb 02, 2017 - German Equity Forum

Company Presentation January

Building integrated and high-value drug discovery alliances
2017-01_Evotec_Company presentation_January